How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy.
"It's clear that nobody had expected that it would be taking off this quickly," said Novo Nordisk CEO Lars Fruergaard Jørgensen in August."We all along knew that obesity was a serious chronic disease also when most others did not see it like that. So we knew we were onto something big." "There has not been any performance near what we've seen over the last year or two," said Jared Holz, health care sector specialist at Mizuho, adding that semaglutide alone could be worth up to $300 billion annually over time.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exclusive: Catalent's Indiana plant to make Novo's Wegovy weight-loss drug-sourcesCatalent's (CTLT.N) plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk's (NOVOb.CO) weight-loss drug Wegovy as part of the two companies' expanded supply agreement, two sources familiar with the matter told Reuters.
Read more »
Exclusive: Novo Nordisk hires private U.S. firm to handle some Wegovy pen assembly -sourceNovo Nordisk (NOVOb.CO) has hired U.S. private contract manufacturer PCI Pharma Services to handle assembly and packaging of Wegovy, a source familiar with the matter said, as it races to boost output of the weight-loss drug to meet demand.
Read more »
Should Walmart be data-mining your Ozempic prescriptions?Walmart says it’s using customer data to see if people who fill Wegovy or Ozempic prescriptions are buying less food, raising privacy questions.
Read more »
Food Stocks Are Falling. Don't Blame Ozempic.Packaged-food stocks are in the red as of late, and it may indicate that consumers are shifting to fresh produce, meat, deli, and bakery products.
Read more »
FDA Adds Warning To Ozempic Label About Ileus, Intestinal BlockageI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
Read more »